"ProFound AI increases my confidence reading 3D mammograms," according to Lisa Sheppard, MD, PINK Breast Center. "We find this technology not only benefits our patients, reducing unnecessary callbacks and giving us more confidence when we recommend biopsies, ProFound AI fits with our workflow and protocols. Ultimately, this helps us continue to improve patient care."

iCAD's flagship product for cancer therapy is the Xoft System, which is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancers (NMSC), and gynecological cancers.


"The Xoft System is an innovative radiation oncology treatment solution that offers significant cost, mobility, and treatment time advantages over competitors or the standard of care," according to Stacey Stevens, President of iCAD. "It offers a clinically-proven, single-fraction therapy for early-stage breast cancer, while also offering added flexibility to treat other types of cancers, including nonmelanoma skin cancers and gynecological cancers."

The Xoft System uses a miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body. For the treatment of early-stage breast cancer, intraoperative radiation therapy (IORT) with the Xoft System allows appropriately selected patients to potentially replace four to six weeks of post-operative external beam radiation therapy (EBRT) with a single-fraction of radiation that can last as little as eight minutes.

The Company recently unveiled new and updated x-ray sources and the full suite of applicators for existing and emerging applications at the American Society for Radiation Oncology (ASTRO) Annual Meeting last year. These included applicators in development for minimally-invasive robotic surgery, such as prostate, an advanced prototype for early-stage rectal cancers, and extended-length balloon applicators, now available in 25 cm and 50 cm lengths, which offer added versatility and the potential for additional applications for Xoft eBx in different areas of the body. The Company also showcased its latest extended-life x-ray sources, which feature a ten-fold increase in treatment times, offering time-saving benefits for clinicians and enhancing efficiency. Additionally, the Company offers world-class treatment planning programs, developed for both the Xoft controller and general IORT with the Xoft System.

Products and Clearances Homepage